- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.03. | Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup | ||
| 28.03. | Boundless Bio breaks IPO lull with $100M fundraise | ||
| 27.03. | Moderna gets Blackstone backing for flu vaccine R&D | ||
| 27.03. | European study finds popular ALS drug ineffective | ||
| 26.03. | Supreme Court weighs abortion opponents' standing in mifepristone case | ||
| 26.03. | FDA approves Merck lung disease drug acquired in $11B deal | ||
| 26.03. | Viking stays in obesity drug race with early data for weight loss pill | ||
| 26.03. | Stoke shares surge on updated results for Dravet drug | ||
| 26.03. | SQZ, Portal founder Armon Sharei on starting over in biotech | ||
| 25.03. | AbbVie to buy immune drug developer Landos | ||
| 25.03. | Axsome drug succeeds in narcolepsy symptoms trial | ||
| 25.03. | FDA rejects Regeneron lymphoma drug, setting back company's oncology push | ||
| 25.03. | Novo to acquire heart failure drug in $1B deal for Cardior | ||
| 25.03. | Improving clinical trial design with real-world data | ||
| 25.03. | The future of companion diagnostic (CDx) development: Why commercialization is key | ||
| 22.03. | FDA clears first-of-its-kind Duchenne drug for broad use | ||
| 22.03. | Medicare to cover Novo's obesity drug for some patients | ||
| 21.03. | NextCure to lay off 37% of staff, dial back research plans | ||
| 21.03. | Roche autoimmune disease drug disappoints in closely watched trial | ||
| 21.03. | Thermo Fisher, Bayer partner to develop companion diagnostics | ||
| 21.03. | Bayer streamlines pharma leadership team amid company shakeup | ||
| 21.03. | Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off | ||
| 20.03. | Acelyrin eye drug heads to late-stage testing after trial win | ||
| 20.03. | Orchard sets out to sell world's priciest gene therapy | ||
| 20.03. | Capstan heats up 'in vivo' cell therapy chase with $175M fundraise |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
